FDA-approved
Bones & muscles
Zilucoplan
Evidence
FDA approved
Class
Complement C5 inhibitor macrocyclic peptide
KEY TAKEAWAY
Zilucoplan is a 15-amino-acid macrocyclic peptide that blocks complement protein C5. It is sold as Zilbrysq. The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.
Written by the Veylo editorial team · Updated
November 2026
What it is
Complement C5 inhibitor macrocyclic peptide
Approved for
Generalized myasthenia gravis in adults with anti-AChR antibodies
Key fact
The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Zilucoplan is a 15-amino-acid macrocyclic peptide that blocks complement protein C5. It is sold as Zilbrysq.
By binding C5, it stops the complement system from attacking the nerve-muscle junction in myasthenia gravis.
The FDA approved zilucoplan (Zilbrysq) in October 2023 for generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor antibodies.
Generalized myasthenia gravis in adults with anti-AChR antibodies.
The label carries a boxed warning for serious meningococcal infections, so vaccination and monitoring are required.
U.S. FDA prescribing information for Zilucoplan. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.